[Risk factors and clinical evolution of carbapenemase-producing Klebsiella pneumoniae infections in a university hospital in Spain. Case-control study]
- PMID: 30229644
- PMCID: PMC6194862
[Risk factors and clinical evolution of carbapenemase-producing Klebsiella pneumoniae infections in a university hospital in Spain. Case-control study]
Abstract
Objective: Carbapenemase-producing Enterobacterias is a global health hazard due to their ease of transmission, difficulty of treatment, and their personal and economic impact. We analyze the factors associated with an increased risk of infection by Klebsiella pneumoniae carbapenemase-producing bacteria (KPC) and factors related to poor prognosis.
Methods: We designed a case-control study. KPC isolates were taken during an outbreak in a hospital in Madrid. A logistic regression was performed with the main variables.
Results: Sixteen cases of clinically documented infections were isolated. Overall mortality rates in the cases group was 25%. The most frequent location was blood (37.5%) followed by urine (25%). All but one were OXA-48. Regarding factors related to an increased risk of developing infection, only previous exposure to antibiotics presented statistical significance difference OR 13 (2.40-70.46). With respect to the overall mortality, the presence of pneumonia OR 25 (1.93-323.55) or the use of invasive mechanical ventilation was associated with greater risk 15 OR 33 (1.92-122.8) For attributable mortality only invasive ventilation had a significant association OR 18 (1.48-218.95).
Conclusions: Exposure to previous antibiotics is an independent risk factor for developing KPC infection, adjusted for all other clinical and demographic variables. Risk factors such as the presence of pneumonia or the use of invasive mechanical ventilation were associated with a worse prognosis in terms of overall and attributable mortality.
Introducción: Las enterobacterias productoras de carbapenemasas son un problema de salud mundial debido a su facilidad de transmisión, la dificultad de tratamiento y su impacto económico y personal. Analizamos los factores asociados a un mayor riesgo de infección por Klebsiella pneumoniae productora de carbapenemasas (KPC) y los factores relacionados con peor pronóstico.
Material y métodos: estudio de casos y controles. Se tomaron los aislamientos de KPC durante un brote en un hospital del sur de Madrid. Con las variables se llevó a cabo una regresión logística.
Resultados: Se aislaron 16 casos causantes de infecciones clínicamente documentadas. La mortalidad global en los casos fue del 25%. La localización más frecuente fue sangre (37,5%), seguida de orina (25%). Todos, excepto uno fueron OXA-48. En cuanto a factores relacionados con mayor riesgo de desarrollar infección, únicamente la exposición previa a antibióticos presentó significación estadística OR 13 (2,40-70,46). Con respecto a la mortalidad global, se asoció a un mayor riesgo la presencia de neumonía OR 25 (1,93-323,55) o el empleo de ventilación mecánica invasiva 15,33 (1,92-122,8). Para la mortalidad atribuible solo la ventilación mecánica invasiva tuvo una asociación significativa OR 18 (1,48-218,95).
Conclusiones: La exposición a antibióticos previos es un factor de riesgo independiente de desarrollar una infección por KPC, ajustado por el resto de variables clínicas y demográficas. Factores de riesgo como la presencia de neumonía o el empleo de ventilación mecánica invasiva se relacionaron con un peor pronóstico en términos de mortalidad global y atribuible.
©The Author 2018. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).
Conflict of interest statement
Los autores declaran no tener ningún conflicto de intereses.
Figures
Similar articles
-
Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes.Infect Control Hosp Epidemiol. 2010 Dec;31(12):1250-6. doi: 10.1086/657135. Epub 2010 Oct 25. Infect Control Hosp Epidemiol. 2010. PMID: 20973725
-
An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae Carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes.Clin Infect Dis. 2010 Feb 1;50(3):364-73. doi: 10.1086/649865. Clin Infect Dis. 2010. PMID: 20041768
-
A ten-year surveillance study of carbapenemase-producing Klebsiella pneumoniae in a tertiary care Greek university hospital: predominance of KPC- over VIM- or NDM-producing isolates.J Med Microbiol. 2016 Mar;65(3):240-246. doi: 10.1099/jmm.0.000217. Epub 2015 Dec 23. J Med Microbiol. 2016. PMID: 26698320
-
Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae: a review of epidemiological and clinical aspects.Expert Opin Biol Ther. 2012 Jun;12(6):663-71. doi: 10.1517/14712598.2012.681369. Epub 2012 Apr 16. Expert Opin Biol Ther. 2012. PMID: 22506862 Review.
-
Mortality due to KPC carbapenemase-producing Klebsiella pneumoniae infections: Systematic review and meta-analysis: Mortality due to KPC Klebsiella pneumoniae infections.J Infect. 2018 May;76(5):438-448. doi: 10.1016/j.jinf.2018.02.007. Epub 2018 Mar 1. J Infect. 2018. PMID: 29477802
Cited by
-
Clinical and Microbiological Risk Factors for 30-Day Mortality of Bloodstream Infections Caused by OXA-48-Producing Klebsiella pneumoniae.Pathogens. 2023 Dec 21;13(1):11. doi: 10.3390/pathogens13010011. Pathogens. 2023. PMID: 38276157 Free PMC article.
-
Tracking KPC-3-producing ST-258 Klebsiella pneumoniae outbreak in a third-level hospital in Granada (Andalusia, Spain) by risk factors and molecular characteristics.Mol Biol Rep. 2020 Feb;47(2):1089-1097. doi: 10.1007/s11033-019-05203-w. Epub 2019 Dec 2. Mol Biol Rep. 2020. PMID: 31792747
-
Klebsiella pneumoniae Isolates from the Intensive Care Unit at South Qunfudah Hospital in Saudi Arabia: An Emerging Antimicrobial Resistance Profile.Infect Drug Resist. 2025 May 13;18:2451-2460. doi: 10.2147/IDR.S500154. eCollection 2025. Infect Drug Resist. 2025. PMID: 40384802 Free PMC article.
-
Update of the treatment of nosocomial pneumonia in the ICU.Crit Care. 2020 Jun 29;24(1):383. doi: 10.1186/s13054-020-03091-2. Crit Care. 2020. PMID: 32600375 Free PMC article. Review.
-
Antimicrobial resistance in Gram-negative bacilli in Spain: an experts' view.Rev Esp Quimioter. 2023 Feb;36(1):65-81. doi: 10.37201/req/119.2022. Epub 2022 Dec 13. Rev Esp Quimioter. 2023. PMID: 36510684 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources